Get the Stockscreener App
1.59
3.05%
-0.05
After Hours:
1.58
-0.01
-0.63%
In 8 Bio Inc stock is traded at $1.59, with a volume of 42,778.
It is down -3.05% in the last 24 hours and down -26.39% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.64
Open:
$1.59
24h Volume:
42,778
Relative Volume:
0.64
Market Cap:
$7.22M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.12
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+2.58%
1M Performance:
-26.39%
6M Performance:
-63.87%
1Y Performance:
-84.23%
1-Day Range:
$1.59
$1.70
1-Week Range:
$1.56
$1.89
52-Week Range:
$1.5301
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.59 | 7.60M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Korro Bio, Inc. (KRRO): RBC Capital Initiates “Sector Perform” Rating with Upside Potential - Stocks Telegraph
[8-K] Instil Bio, Inc. Reports Material Event | TIL SEC FilingForm 8-K - Stock Titan
[8-K] Annovis Bio, Inc. Reports Material Event | ANVS SEC FilingForm 8-K - Stock Titan
[S-8] PALISADE BIO, INC. Employee Benefit Plan Registration | PALI SEC FilingForm S-8 - Stock Titan
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Inmune Bio, Inc. Announces Key Developments in Clinical Programs - TradingView
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
[8-K] Cabaletta Bio, Inc. Reports Material Event | CABA SEC FilingForm 8-K - Stock Titan
Belite Bio Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
KALA BIO Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire Inc.
[8-K] Climb Bio, Inc. Reports Material Event | CLYM SEC FilingForm 8-K - Stock Titan
[8-K] Gossamer Bio, Inc. Reports Material Event | GOSS SEC FilingForm 8-K - Stock Titan
Gossamer Bio Inc reports results for the quarter ended September 30Earnings Summary - TradingView
[PRE 14A] Adicet Bio, Inc. Preliminary Proxy Statement - Stock Titan
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
TELA Bio to Announce Third Quarter 2025 Financial Results - GlobeNewswire
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Gossamer Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
[Form 4] TELA Bio, Inc. Insider Trading Activity - Stock Titan
[Form 3] TELA Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan
[8-K] TELA Bio, Inc. Reports Material Event | TELA SEC FilingForm 8-K - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October - Defense World
[8-K] Protagenic Therapeutics, Inc.new Reports Material Event | PTIX SEC FilingForm 8-K - Stock Titan
Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
ANVS prices registered direct; directors buy 1.07M shares at $2.05 - Stock Titan
INMB to discuss Q3 2025 results on Oct 30, 4:30 p.m. ET - Stock Titan
Tourmaline Bio Announces Board and Executive Resignations Following Merger - TradingView
[8-K] Tourmaline Bio, Inc. Reports Material Event | TRML SEC FilingForm 8-K - Stock Titan
Why Nuvation Bio Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Safe Investment Ideas - fcp.pa.gov.br
Cabaletta Bio, Inc. Presents Clinical Data and Updates at ACR Convergence 2025 - TradingView
INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 - Stock Titan
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
Q32 Bio Inc Completes Enrollment in SIGNAL-AA Phase 2a Trial - TradingView
[8-K] bioAffinity Technologies, Inc. Reports Material Event | BIAF SEC FilingForm 8-K - Stock Titan
PALI annual meeting: directors elected, auditor ratified, split approved - Stock Titan
Stop Loss: Why Nuvation Bio Inc. stock is popular among millennials2025 Sector Review & Breakout Confirmation Alerts - Trung tâm Dự báo KTTV quốc gia
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia - KED Global
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan
CLYM reports budoprutug Phase 1b follow-up: 3-year control in 4 pts - Stock Titan
Palisade Bio Provides Corporate and Compliance Update - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
ANVS prices $6.0M offering; adds pre-funded and agent warrants - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):